Is Trastuzumab an immune drug or a targeted drug?

Trastuzumab (Trastuzumab) is a targeted prescription drug. It is a monoclonal antibody that blocks the growth and division of HER2-positive breast cancer cells by specifically binding to and inhibiting the function of human epidermal growth factor receptor 2 (HER2). Because of its mechanism of action that targets specific molecules, trastuzumab is classified as a targeted drug rather than an immune drug.

Trastuzumab is a humanizedIgG1 light chain monoclonal antibody in which the complementarity determining region (CDR) of a HER2-specific mouse monoclonal antibody is genetically engineered to link to the human antibody framework region. Trastuzumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer in the adjuvant and metastatic settings. However, a large number of patients with HER2-overexpressing breast cancer will initially or eventually become resistant to anti-HER2 therapy with trastuzumab. As an antibody, trastuzumab has several properties that are either related to its Fab and/or Fc functions.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.